Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? - Wikidata - awgldk - TriplyDB

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

http://www.wikidata.org/entity/Q34573884

about

Hematopoietic stem cell transplantation: a global perspective Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia An update of current treatments for adult acute myeloid leukemia Allogeneic stem cell transplantation in first complete remission Progress in acute myeloid leukemia Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments Novel therapeutic options in Acute Myeloid Leukemia 'Acute myeloid leukemia: a comprehensive review and 2016 update'Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations.Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.Molecular therapy for acute myeloid leukaemia.Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.Advances in treating acute myeloid leukemia.Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission Dual processing model of medical decision-making.A practical approach for a wide range of liver iron quantitation using a magnetic resonance imaging technique.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.The EBMT Risk Score in the Presence of Graft Versus Host Disease in Allogeneic Stem Cell Transplantation in Adult Acute Myelogenous Leukemia: A Multistate Model for Competing Risks Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials networ The treatment of elderly patients with acute myeloid leukemia.Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.Dual Processing Model for Medical Decision-Making: An Extension to Diagnostic Testing.Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission.Survival analysis in hematologic malignancies: recommendations for clinicians

P2860

Q24624697-1C87C4C8-A09F-4CF0-A776-4C47CA2F338E Q26771438-E0D8A47D-5A17-461A-A079-322E1EB71655 Q26776396-9A3BDAF4-2478-42A0-ACA3-80F3EC39A256 Q26996818-D02DC3E0-412B-4AAD-AD15-BC4413DBB87C Q27024006-EE3E27A0-76A1-45A8-A5A3-93EDAB9CDBAE Q28067102-AC72E98D-6AA4-409B-BAFB-B7B9E8942441 Q28069889-1DBC573C-1010-4ED8-9AFE-73138082D9F6 Q28072539-B0E495D5-0490-43BE-BBF0-499C8D96415F Q28075654-5D6D0D6C-2948-488B-B6BF-8273D62511BD Q30315865-A22927CB-A124-4B72-A6BF-5D1447869939 Q31052875-CE8F4C8D-2F9D-433F-AF26-16A4037EC775 Q33555627-59296404-EAA7-4C55-9684-E0ACD9148EEC Q33645271-72BED86D-98B4-4A4F-A3C1-014CE74620B6 Q33760933-B74DC413-B74B-48F8-92E7-17C71DAD0C14 Q33832709-A1815612-6D86-41A3-B252-924D2FEA8AA4 Q33841129-78FB89CF-B3FF-4DFA-8D21-81B640B23804 Q33925672-A38C7E23-7698-46D2-9064-3EB16CC92C08 Q34033553-51EFB4A4-3267-48F3-A1F1-9BA710DC30DF Q34166581-D4E14321-B5F5-487A-B2A0-70E2CB8EEAAB Q34167404-2D63E9C7-760E-4097-B1B6-CB8F283AF5A6 Q34243434-9B245751-814B-4D13-8A78-5C858A582F48 Q34255090-E130EBA4-389D-4E5F-A4CE-372914F163C4 Q34312351-92006CB6-1D33-48A7-8662-AC444152DB62 Q34401926-46AEB1AA-B355-43EA-869A-2C8F49A2D022 Q34401953-F82991AF-17CF-48D9-9498-A99E8DDDDB1B Q34568446-6626D21B-A57F-405C-9FA9-10230C410440 Q34608688-4D534A36-76F0-4711-8CFD-9794CC04EDAB Q34620456-9771CFA4-D556-4510-A165-67150AC6E3B1 Q34655572-1C6CB599-0C47-4BC9-B55C-D93AB45C6668 Q34877613-4D820B3B-631A-42E9-B7E9-6030812AF3F9 Q35009266-5B6B433F-4EBD-40A8-8508-121F72B95A08 Q35082499-BC5B9AB1-9CA3-4AA2-9347-C17643894CFD Q35148420-1A3BD6A1-C5DA-4C5C-A4E2-D5CE00B6B476 Q35673578-F8C736B5-1C07-4CAC-ACB2-63503E8EC4BF Q35703480-861D2C85-F9A6-4EB3-9467-D26349DBC272 Q35800814-05512A04-DCBE-4C05-BAB7-B555B65A32D3 Q35921388-931E2CE8-5BA0-40AA-84A6-C8DF66577839 Q35953348-B8FF0B18-69BF-417D-A418-C7AD28AFC1EF Q36006412-D7F7E72D-40DE-4485-9F02-0EA3FE9D4F85 Q36036279-1287B206-3A05-40E6-B94B-AA8478854E30

P2860

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

http://www.wikidata.org/entity/Q34573884

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

Results of a HOVON/SAKK donor ...... ged adults: benefits for whom?

@ast

Results of a HOVON/SAKK donor ...... ged adults: benefits for whom?

@en

Results of a HOVON/SAKK donor ...... ged adults: benefits for whom?

@nl

type

label

Results of a HOVON/SAKK donor ...... ged adults: benefits for whom?

@ast

Results of a HOVON/SAKK donor ...... ged adults: benefits for whom?

@en

Results of a HOVON/SAKK donor ...... ged adults: benefits for whom?

@nl

prefLabel

Results of a HOVON/SAKK donor ...... ged adults: benefits for whom?

@ast

Results of a HOVON/SAKK donor ...... ged adults: benefits for whom?

@en

Results of a HOVON/SAKK donor ...... ged adults: benefits for whom?

@nl

P1433

Q34573884-03D3F404-10B5-4D72-BF44-3C6B01B2880B

P1476

Q34573884-514887B1-AD69-4DE2-A483-4C4538CCD681

P2093

Q34573884-0065B119-43A9-48A2-9899-E9A31E308EA2

Q34573884-09F14CE2-05CC-4FA7-869C-FEADE27125C9

Q34573884-4BC0833C-25ED-4F5B-A88C-5F08F3682829

Q34573884-6C819331-0B4A-4132-9966-82A622413C34

Q34573884-709FBC33-ADB6-44C0-8263-70664AF32D4C

Q34573884-7778AB08-6D11-44AB-8F4C-02F5EB9FD682

Q34573884-815BBD90-A908-4353-A711-887945F23DA6

Q34573884-949594CB-2EEB-4122-8B7F-AEF95649BD9C

Q34573884-9A268766-A032-4C24-A0B2-593318BB662A

Q34573884-A228E26F-FEB2-4C4A-9EF6-16BA1EFE6356

P304

Q34573884-B3BF5C1D-49A7-413C-A215-FF75AF165C49

P31

Q34573884-90DD6730-EE1C-48CA-B179-607987676584

P356

Q34573884-AB1D3AEC-2568-4235-AF09-590F448E2BAD

P407

Q34573884-5CC43AD7-DC17-4FB3-BFA9-91D0C2D8B5BE

P433

Q34573884-32503825-0776-49C3-A30A-379BA7933437

P478

Q34573884-D36DC3F5-1DE0-49C1-8625-8EA1CF683B55

P50

Q34573884-3E0E997B-35D3-4AB0-A87E-09218EA87407

Q34573884-9C79A0D1-14A3-4153-9BE9-44EB0DBDD1D9

P577

Q34573884-7FCA06F0-4867-4B9E-8451-FB6E6A1F8D68

P5875

Q34573884-57963A95-46CB-4CAB-8DEC-FE9A1B92D1C3

P698

Q34573884-A4D375F9-CD6C-4E59-9272-840CDD3A0368

P921

Q34573884-6AD97FC6-782B-4602-9A60-5EF6032D0AFF

Q34573884-A933D527-BB3A-4703-BCE9-DC2579E0DAB3

P356

BLOOD-2006-06-025627

P1433

P1476

Results of a HOVON/SAKK donor ...... ged adults: benefits for whom?

@en

P2093

Augustin Ferrant

http://www.w3.org/2001/XMLSchema#string

Emanuel Jacky

http://www.w3.org/2001/XMLSchema#string

Hans van der Lelie

http://www.w3.org/2001/XMLSchema#string

Harry Schouten

http://www.w3.org/2001/XMLSchema#string

Jan J Cornelissen

http://www.w3.org/2001/XMLSchema#string

Johan Maertens

http://www.w3.org/2001/XMLSchema#string

Leo F Verdonck

http://www.w3.org/2001/XMLSchema#string

Marinus van Marwijk Kooy

http://www.w3.org/2001/XMLSchema#string

Martin Fey

http://www.w3.org/2001/XMLSchema#string

Matthias Theobald

http://www.w3.org/2001/XMLSchema#string

P304

3658-3666

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-06-025627

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6588688

http://www.w3.org/2001/XMLSchema#string

P698

17213292

http://www.w3.org/2001/XMLSchema#string

P921